M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Bivalirudin in Acute Coronary Syndromes. Authors reply.
Marco Valgimigli,Andrea Santucci +1 more
TL;DR: The bivalirudin-mediated vascular immobilization of neutrophil-derived myeloperoxidase might contribute to early stent thrombosis during acute myocardial infarction as a result of the inactivation of endogenous nitric oxide that occurs before there is fully effective platelet inhibition, just after loading doses of oral P2Y12 antagonists have been administered.
Journal ArticleDOI
Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome.
P. Gabriel Steg,Michael Szarek,Marco Valgimigli,Shahidul Islam,Andreas M. Zeiher,Deepak L. Bhatt,Vera Bittner,Chern-En Chiang,Rafael Diaz,Shaun G. Goodman,Nina Gotcheva,Robert A. Harrington,J. Wouter Jukema,Hyo-Soo Kim,Sang-hyun Kim,João Morais,Robert Pordy,Michel Scemama,Harvey D. White,Gregory G. Schwartz +19 more
TL;DR: In this article , the authors explored whether risk of revascularization after acute coronary syndrome (ACS) was modified by the level of lipoprotein(a) and treatment with alirocumab or placebo.
Journal ArticleDOI
Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention: Is Access Site the New Piece of the Puzzle?
Journal ArticleDOI
Antithrombotic therapy in patients with established atherosclerotic coronary disease
Antonio Landi,Marco Valgimigli +1 more
TL;DR: In this article , the authors provide an update of available evidence on antithrombotic treatment regimens for secondary or tertiary prevention in patients with established coronary artery disease based on different ischaemic and/or bleeding risk profiles.
Journal ArticleDOI
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.
Marco Valgimigli,Enrico Frigoli,Pascal Vranckx,Yukio Ozaki,Marie-Claude Morice,Bernard Chevalier,Yoshinobu Onuma,Stephan Windecker,Laurent Delorme,Petr Kala,Sasko Kedev,Rajpal K. Abhaichand,Vasil Velchev,Willem Dewilde,Jakub Podolec,Gregor Leibundgut,Dragan Topic,C. Schultz,Goran Stankovic,Astin Lee,Thomas C. Johnson,Pim A.L. Tonino,Aneta Klotzka,Maciej Lesiak,Renato D. Lopes,Pieter C. Smits,Dik Heg +26 more
TL;DR: In this article , the authors investigated the impact of nonadherence to study protocol regimens in the MASTER DAPT (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPTs) trial.